Mackenzie Financial Corp Buys 40,793 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)

Mackenzie Financial Corp raised its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 173.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 64,293 shares of the medical instruments supplier's stock after purchasing an additional 40,793 shares during the quarter. Mackenzie Financial Corp owned approximately 0.16% of AngioDynamics worth $589,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Systematic Financial Management LP boosted its holdings in shares of AngioDynamics by 4.6% during the 4th quarter. Systematic Financial Management LP now owns 2,521,065 shares of the medical instruments supplier's stock valued at $23,093,000 after buying an additional 110,719 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of AngioDynamics by 10.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,488,667 shares of the medical instruments supplier's stock valued at $13,636,000 after buying an additional 135,007 shares in the last quarter. Segall Bryant & Hamill LLC boosted its holdings in shares of AngioDynamics by 55.3% during the 4th quarter. Segall Bryant & Hamill LLC now owns 1,415,156 shares of the medical instruments supplier's stock valued at $12,963,000 after buying an additional 503,713 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in shares of AngioDynamics by 37.4% during the 4th quarter. Nuveen Asset Management LLC now owns 1,296,366 shares of the medical instruments supplier's stock valued at $11,875,000 after buying an additional 353,070 shares in the last quarter. Finally, Royce & Associates LP boosted its holdings in shares of AngioDynamics by 13.5% during the 4th quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier's stock valued at $10,254,000 after buying an additional 133,312 shares in the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and set a $16.00 target price (up previously from $15.00) on shares of AngioDynamics in a report on Monday, April 7th.

AngioDynamics Stock Up 0.9%

Shares of ANGO stock traded up $0.10 during mid-day trading on Friday, reaching $11.06. 765,700 shares of the company's stock traded hands, compared to its average volume of 573,297. AngioDynamics, Inc. has a 12 month low of $5.47 and a 12 month high of $13.50. The company's 50-day moving average price is $9.55 and its 200-day moving average price is $9.67. The company has a market cap of $449.11 million, a P/E ratio of -1.96 and a beta of 0.62.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 2nd. The medical instruments supplier reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.13) by $0.16. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company had revenue of $72.00 million for the quarter, compared to the consensus estimate of $70.30 million. The firm's revenue for the quarter was down 4.3% compared to the same quarter last year. Equities analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.